Parkinson’s

Mitochondria
#Mission Therapeutics #Neuroscience #Parkinson's #Phase I trial

Mission doses first Parkinson’s patient in Phase Ib study

Mission Therapeutics has dosed the first patient in its Phase Ib proof-of-mechanism study of MTX325 in patients with Parkinson’s disease (PD).  MTX325 is a first-in-class, highly potent and selective, orally bioavailable and brain-penetrant inhibitor of the deubiquitinating enzyme (DUB) USP30.   It has been designed to… Read More

#News

Parkinson's disease
#Drug discovery #Lundbeck #Parkinson's

Phase Ib data in advanced Parkinson’s disease released as Phase II trial begins 

Lundbeck has announced results from an open-label Phase Ib trial evaluating Lu AF28996, a novel, investigational, oral prodrug of D1-like/D2-like dopamine receptor agonist, in people with advanced Parkinson’s disease experiencing motor symptoms sub-optimally controlled despite optimised non-invasive antiparkinsonian medication.    The results are being presented at the… Read More

#News

#Genentech #License agreement #Neuroscience #Parkinson's

Genentech licenses enzyme replacement therapy for Parkinson’s

Alector has granted Genentech worldwide rights to develop and commercialise its AL050 programme, a brain-penetrant engineered glucocerebrosidase (GCase) enzyme replacement therapy (ERT).  As part of the deal, Alector will receive a $100 million upfront payment, with potential for up to $1.17 billion in additional milestone payments, as well as tiered… Read More

#Business & Investment #News

Sleep study in older man
#AstronauTx #Funding #Neuroscience #Parkinson's

Grants support research into sleep mechanisms in Parkinson’s

AstronauTx has received funding from The Michael J Fox Foundation for Parkinson’s Research (MJFF), while Parkinson’s UK is funding an additional complementary research effort in collaboration with University College London (UCL).  The MJFF-funded project, titled ‘Ligand-Gated Ion Channel Modulation as a Disease-Modifying Treatment for Prodromal Synucleinopathies’, will… Read More

#News

Neuroscience Parkinson's disease
#Ariadne Bio #Neurodegenerative disorders #Neuroscience #Parkinson's #Spinout #Start-ups

Ariadne Bio spins out to target apathy in Parkinson’s disease

Palomar Labs (formerly Negev Labs), a venture studio that builds companies around neuropsychiatric drug development programmes with prior human validation, has announced the spinout of Ariadne Bio, its first portfolio company.   Ariadne Bio launches with lead programme AB-300, a clinical-stage-ready, non-hallucinogenic serotonin 2A receptor agonist in development for apathy in… Read More

#Business & Investment #News #Start-up Zone

Human brain
#Neurodegenerative disorders #Neuroscience #Parkinson's #Phase I trial #Teitur Trophics

Phase I trial shows Parkinson’s peptide crosses blood-brain barrier

Teitur Trophics has announced successful results from its Phase I clinical trial of lead asset TT-P34 in healthy volunteers and patients with early-stage Parkinson’s disease (PD).  The data show TT-P34 crosses the blood-brain barrier, leading to robust, dose-dependent exposure within the brain and central nervous system (CNS). Read More

#News

Neurons
#AC Immune #Immunotherapy #Neuroscience #Parkinson's #US Food and Drug Administration (FDA)

Immunotherapy for Parkinson’s gets FDA Fast Track Designation

AC Immune has received Fast Track designation and clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) for its anti-alpha-synuclein (a-syn) active immunotherapy candidate, ACI-7104, for the treatment of early-stage Parkinson’s disease (PD).  ACI-7104 is designed to induce a-syn-specific antibodies, preferentially recognising aggregated… Read More

#Editor's Choice #News #Regulatory

Parkinson's disease
#BioVie #Neuroscience #Parkinson's #Phase II trial

Trial shows significant improvements in early Parkinson’s disease

BioVie has announced results from its Phase II SUNRISE-PD trial evaluating its drug candidate bezisterim in early-stage Parkinson’s disease (PD).  The SUNRISE-PD trial was a Phase II, multicentre, randomised, double-blind, placebo-controlled trial designed to establish proof-of-mechanism and proof-of-concept in patients with early-stage PD that had not previously… Read More

#Editor's Choice #News

#Alzheimer's #Alzheimer's Drug Discovery Foundation #Biomarkers #Drug discovery #Parkinson's #Partnership #The Michael J Fox Foundation #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

US$5m partnership targets Alzheimer’s and Parkinson’s biomarkers

The Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator (DxA) and The Michael J. Fox Foundation (MJFF) have announced a new US$5 million partnership to accelerate the development of minimally invasive biomarkers for measuring pathologies associated with Parkinson’s and Alzheimer’s diseases. Isobel Coleman, Chief Executive Officer of the Alzheimer’s Drug Discovery… Read More

#News

Neuroscience Parkinson's disease
#Biology #Drug discovery #Neuroscience #Parkinson's

Parkinson’s disease and CDNF: Turning a neurotrophic factor into a viable therapy 

Henri Huttunen CSO of Herantis Pharma discusses the challenges of using neurotrophic factors as a treatment for Parkinson’s disease.   Many successful drugs originate from molecules that already exist within the human body. Hormones, neurotransmitters and other endogenous molecules perform essential biological functions, making them attractive starting points for therapeutic development. If a… Read More

#Exclusive Content

World Parkinson's Day
#AskBio #Blood brain barrier #FDA #Gene therapy #Parkinson's #Regulatory

How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease

Bruno Quinney speaks to Adrian Kells, Senior Vice President and Integrated Product Team Lead PD at AskBio, about the company’s gene therapy programme and pioneering treatment for Parkinson’s. The drug discovery landscape for Parkinson’s disease is becoming one of the most exciting frontiers in the industry. It is unsurprising to… Read More

#Exclusive Content

Alzheimer's disease drug
#Alzheimer's #FDA #Herantis Pharma #Parkinson's

Herantis to advance Alzheimer’s treatment after FDA meeting 

Herantis is set to advance the clinical development of its Alzheimer’s therapy following a positive meeting with the US Food and Drug Administration (FDA).  The company reports it completed a pre-IND meeting with the FDA to discuss the planned clinical development of HER-096, a first-in-class small peptide being developed to treat Alzheimer’s disease. … Read More

#News #Regulatory

#Parkinson's #R&D #UK

UK centre opens to accelerate Parkinson’s treatment research 

A new UK research centre has opened to accelerate the search for treatments for Parkinson’s disease.   The £10 million ($13.5 million) UK Dementia Research Institute Parkinson’s Research Centre, jointly funded with Parkinson’s UK, will connect research teams at the University of Edinburgh, the University of Oxford and University College London. Read More

#News

#Cancer research #Drug discovery #Enzymes #Myeloma #Parkinson's #University of Edinburgh

DDW Highlights: 26 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates the key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a cancer enzyme discovery provided clues for potential new treatments. Elsewhere, how can… Read More

#Podcasts

#Bacteria #Blood cancer #Cancer Research UK #HaemaLogiX #Haematology #Institute of Cancer Research #Myeloma #Neuroscience #NHS #Oncology #Orphan drugs #Parkinson's #Rare diseases #University of Edinburgh

This week in Drug Discovery (16 – 20 March) 

News round-up for 16 – 20 March February by Bruno Quinney, Content Team at DDW.  This week, a pioneering method is being used to make drugs for Parkinson’s disease. Elsewhere, advances have been made in both research and trials for common cancers.  The top stories:    Edinburgh team… Read More

#News

#Alzheimer's #Brain #Breast cancer #Dementia #Genetics #Immunology #Institute of Cancer Research #King's College London #Neuroscience #Parkinson's #Respiratory syncytial virus #Women's health

DDW Highlights: 17 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research on the brain proved a popular theme, unlocking insights into Alzheimer’s, dementia… Read More

#Podcasts